secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001104659-26-007423
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio holds webinar Jan 28, 2026; no clinical or financial data furnished
-------------------------------------------------------------------------------

- Company conducted a webinar with CEO Maria Maccecchini; no new results or data disclosed in filing.
- Exhibit 99 contains only a title slide and standard forward-looking statement, no financial or clinical details.
- No guidance, trial updates, or material business developments were provided in the 8-K exhibit.
- Filing is procedural Regulation FD disclosure for the webinar event itself, not a substantive update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926007423/0001104659-26-007423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926007423/tm264292d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-007423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer